Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
GLPG
Galapagos N.V.
GLPG3667 TYK2 inhibitor represents an oral small-molecule therapeutic program.
|
$2.05B |
$31.07
-0.14%
|
|
MESO
Mesoblast Limited
Direct product category: allogeneic mesenchymal lineage cell therapy platform and approved product Ryoncil.
|
$2.04B |
$18.29
+3.27%
|
|
ATRC
AtriCure, Inc.
AtriCure directly manufactures surgical equipment and devices used in operating rooms and minimally invasive cardiac procedures.
|
$2.04B |
$41.19
+0.37%
|
|
SYRE
Spyre Therapeutics, Inc.
Spyre's pipeline comprises engineered monoclonal antibodies (SPY001/SPY002/SPY003) targeting α4β7, TL1A, and IL-23 for IBD and RA.
|
$2.01B |
$32.93
-1.23%
|
|
PRCT
PROCEPT BioRobotics Corporation
PROCEPT's Aquablation robotic systems are surgical equipment sold for urology procedures.
|
$2.01B |
$35.44
-1.83%
|
|
OMCL
Omnicell, Inc.
XT Series automated dispensing systems, XR2 robot, IVX compounding robot are medical devices and biometrics products.
|
$1.99B |
$44.35
+2.50%
|
|
SGRY
Surgery Partners, Inc.
Operates outpatient surgery centers and ASCs, the core service offering and revenue driver.
|
$1.98B |
$15.54
+0.65%
|
|
MD
Pediatrix Medical Group, Inc.
Provides hospital-based neonatal and maternal-fetal care services (NICU care and maternal-fetal medicine) delivered in hospital settings.
|
$1.98B |
$22.46
-1.01%
|
|
SKWD
Skyward Specialty Insurance Group, Inc.
Accident & Health activities include health insurance lines (group stop-loss and related A&H offerings).
|
$1.98B |
$48.87
+0.14%
|
|
QDEL
QuidelOrtho Corporation
QuidelOrtho directly develops diagnostic instruments and platforms (including molecular diagnostics platforms) used in labs, aligning with Diagnostic Equipment.
|
$1.97B |
$28.55
-1.75%
|
|
IMNM
Immunome, Inc.
Primary modality across the pipeline is Antibody-Drug Conjugates (ADCs).
|
$1.97B |
$23.39
+3.31%
|
|
TXG
10x Genomics, Inc.
TXG directly manufactures and sells diagnostic instrument platforms for single-cell and spatial biology workflows.
|
$1.96B |
$15.44
-2.06%
|
|
ZYME
Zymeworks Inc.
Zymeworks develops oncology therapeutics, including zanidatamab and multiple ADC/MSAT platform programs.
|
$1.95B |
$25.91
-0.23%
|
|
SEM
Select Medical Holdings Corporation
Direct hospital services provider; SEM's core revenue comes from Hospital Services including inpatient rehabilitation and CIRH.
|
$1.94B |
$15.29
-2.21%
|
|
KN
Knowles Corporation
Knowles has a significant MedTech / medical device presence via advanced microphones and related audio components used in medical devices.
|
$1.93B |
$22.38
-0.49%
|
|
ZLAB
Zai Lab Limited
Core oncology focus across a deep late-stage pipeline including multiple oncology antibodies and ADC assets.
|
$1.91B |
$17.05
-1.67%
|
|
SION
Sionna Therapeutics, Inc.
Lead candidates are oral small-molecule therapeutics (SION-719, SION-451) in clinical development.
|
$1.89B |
$42.84
+0.20%
|
|
TWST
Twist Bioscience Corporation
Twist's antibody libraries for drug discovery align with the Antibody Discovery Platform investable theme.
|
$1.88B |
$30.64
-1.38%
|
|
LMAT
LeMaitre Vascular, Inc.
Directly produces vascular interventional devices (grafts, patches, shunts, catheters) used in vascular surgery.
|
$1.87B |
$82.91
+0.16%
|
|
AVAH
Aveanna Healthcare Holdings Inc.
AVAH directly provides Home Health and Hospice services to patients in home settings.
|
$1.86B |
$8.81
-0.84%
|
|
VCEL
Vericel Corporation
Vericel's core offerings are autologous cell therapies (MACI and Epicel), placing the company in the cell therapy space.
|
$1.84B |
$35.22
-3.48%
|
|
OGN
Organon & Co.
Directly manufactures/markets medical devices (Nexplanon implant and Jada System) used in women's health and obstetric care.
|
$1.82B |
$6.92
-1.42%
|
|
RXRX
Recursion Pharmaceuticals, Inc.
Collaborations with pharma partners and outsourced discovery work resemble a CRO-type service model.
|
$1.82B |
$4.18
-0.36%
|
|
IMCR
Immunocore Holdings plc
KIMMTRAK is an oncology immunotherapy (melanoma) core product; Immunocore's pipeline expands the platform into oncology.
|
$1.81B |
$36.46
+1.22%
|
|
STOK
Stoke Therapeutics, Inc.
TANGO uses antisense oligonucleotides to upregulate the healthy gene copy, directly categorizing the company’s core assets as an oligonucleotide therapeutic.
|
$1.81B |
$33.03
+0.17%
|
|
CLDX
Celldex Therapeutics, Inc.
Barzolvolimab is a therapeutic monoclonal antibody, placing Celldex in Monoclonal Antibody Therapeutics.
|
$1.80B |
$26.70
-1.44%
|
|
SNDX
Syndax Pharmaceuticals, Inc.
Company focuses on oncology therapeutics, including Revuforj and Niktimvo, placing Syndax in Biotech - Oncology.
|
$1.80B |
$20.91
+0.12%
|
|
ANIP
ANI Pharmaceuticals, Inc.
Generics business forms a major revenue stream, with numerous generic products and the Prucalopride CGT-exclusive launch.
|
$1.77B |
$81.28
-0.29%
|
Showing page 11 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
